Auto-generated: February 11 2012 04:51 PM GMT-8

7
Stars
Star This?

Source: AIDS  |  Posted 8 years ago

Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting

Oxymetholone, an anabolic steroid, appears to be effective in countering wasting among HIV positive patients taking highly active antiretroviral therapy (HAART).

This finding results from a double-blind, randomised, placebo-controlled trial at the University of Essen, and the University of Bonn, Germany. Eighty nine HIV-positive women and men participated.

Chronic involuntary weight loss is a serious problem among patients on HAART. The alterations in energy metabolism and endocrine regulation cause loss of lean body mass (LBM) and body cell mass (BCM).

There has been partial restoration of LBM in studies among HIV-positive men undergoing androgen replacement therapy, or treatment with recombinant growth hormone. However, these treatments have largely been ineffective among eugonadal individuals.

In the present study, the men and women with wasting were given oxymetholone 50 mg twice (BID), or three times daily (TID), or placebo for 16 weeks, followed by open-label treatment. Endpoints were body weight, bioimpedance measurements, and appetite.

The clinicians found that oxymetholone produced a significant weight gain of 3.0

7
Stars
Star This?  Yes / No
 
Sign InSign In
inst val